In 2019, using syngeneic bilateral tumor models in which only one lesion receive radiotherapy, they demonstrated that TGFß blockade enhances radiotherapy abscopal effects in combination with anti-PD-1 and anti-CD137 immunostimulatory monoclonal antibodies. The gene discussed is PDCD1; the disease is neoplasm.